ANTI-PD1 ANTIBODIES AND METHODS OF USE

• US 20170247454A1
• Filed: 09/29/2016
• Published: 08/31/2017
• Est. Priority Date: 10/02/2015
• Status: Abandoned Application

• Current Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Original Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Inventors: Benz, Joerg, Deak, Laura Codarri, Dengl, Stefan, Fenn, Sebastian, Fischer, Jens, Georges, Guy, Klein, Christian, Levitski, Viktor, Lifke, Valeria, Ploettner, Oliver, Seeber, Stefan, Weiser, Barbara, Wuensche, Ildiko, Zwick, Adrian
• Application Number:
  US15/280,810
• Publication Number:
  US 20170247454A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to anti-PD1 antibodies and methods of using the same.

Claims

1. An isolated antibody that binds to human PD1, wherein the antibody binds to the (core) sugar chain at Asn58 of glycosylated human PD1 of SEQ ID NO:

70 which is glycosylated at Asn58.

2. The antibody according to claim 1 wherein the antibody binds additionally to one or more amino acids of positions 60 to 64, 68, 78 to 84, 126 to 134 of human PD1.

3. The antibody according to claim 1, wherein the antibody binds with its heavy chain to the sugar chain at Asn58.

4. The antibody according to claim 2, wherein the antibody binds to one or more amino acids of positions 61, 62, 64, 83, 126, 128, 132, 134 of human PD1.

5. The antibody according to claim 3, wherein the antibody binds to amino acids of positions 61, 62, 64, 83, 126, 128, 132, 134 of human PD1.

6. The antibody according to claim 2, wherein the antibody binds to acids of positions 60, 61, 62, 63, 64 68, 78, 82, 83, 84, 126, 127, 128, 130, 131, 132, 133, 134 of human PD1.

7. The antibody according to claim 1, wherein the antibody binds to human PD1, wherein the antibody binds to the first and second GlNac, FUC, BMA and MAN within the (core) sugar chain at Asn58 of glycosylated human PD1 of SEQ ID NO:

70, which is glycosylated at Asn58.

8. The antibody according to claim 1, wherein the antibody shows reduced binding to human PD1 of SEQ ID NO:

70 which is not glycosylated at Asn58 compared to the binding to human PD1 which is glycosylated at Asn58.

33. A method of treating an individual having cancer comprising administering to the individual an effective amount of the antibody of claim 1.

9. An isolated antibody that binds to human PD1, wherein the antibody comprises

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:

71;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

72;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO;

73;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

74;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

75;

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

76, and (g) FR-H3 comprising the amino acid sequence of SEQ ID NO;

77 (of RDN) at positions of 71, 72 and 73 according to Kabat numbering

10. The isolated antibody that binds to human PD1 according to claim 9, wherein the antibody

A)

i) comprises a VH sequence of SEQ ID NO:

7 and a VL sequence of SEQ ID NO;

8;

ii) or humanized variant of the VH and VL of the antibody under i);

or B)

i) comprises a VH sequence of SEQ ID NO;

57 and a VL sequence of SEQ ID NO;

58.

ii) comprises a VH sequence of SEQ ID NO;

57 and a VL sequence of SEQ ID NO;

59.

iii) comprises a VH sequence of SEQ ID NO;

57 and a VL sequence of SEQ ID NO;

60.

iv) comprises a VH sequence of SEQ ID NO;

57 and a VL sequence of SEQ ID NO;

61.

23. The antibody of according to any one of claims 9 to 18, which is a full length IgG1 antibody with mutations L234A, L235A and P329G (numbering according to the EU index of Kabat)

24. Isolated nucleic acid encoding the antibody according to any one of claims 9 to 18.

25. A host cell comprising the nucleic acid of claim 24.

26. A method of producing an antibody comprising culturing the host cell of claim 25 so that the antibody is produced.

27. The method of claim 26, further comprising recovering the antibody from the host cell.

28. A pharmaceutical formulation comprising the antibody according to any one of claims 9 to 18.

11. An isolated antibody that binds to human PD1, wherein the antibody comprises

A) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:

1;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

2;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO;

3;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

4;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

5; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

6;

or

B) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

9;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

10;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO;

11;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

12;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

13; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

14;

or

C) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

17;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

18;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO;

19;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

20;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

21; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

22;

or

D) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

25;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

26;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO;

27;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

28;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

29; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

30;

or

E) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

33;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

34;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO;

35;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

36;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

37; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

38;

or

F) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

41;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

42;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO;

43;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

44;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

45; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

46;

or

G) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

49;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

50;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO;

51;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

52;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

53; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

54.

12. An isolated antibody that binds to human PD1, wherein the antibody comprises

A) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:

1, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

2, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO;

3; and

(b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

4;

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

5 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

6;

or

B) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

9, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

10, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO;

11; and

(b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

12;

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

13 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

14;

or

C) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

17, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

18, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO;

19; and

(b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

20;

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

21 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

22;

or.

D) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

25, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

26, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO;

27; and

(b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

28;

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

29 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

30;

or

E) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

33, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

34, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO;

35; and

(b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

36;

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

37 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

38;

or

F) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

41, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

42, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO;

43; and

(b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

44;

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

45 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

46;

or

G) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

49, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

50, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO;

51; and

(b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

52;

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

53 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

54.

13. An isolated antibody that binds to human PD1, wherein the antibody

A)

i) comprises a VH sequence of SEQ ID NO:

7 and a VL sequence of SEQ ID NO;

8;

ii) or humanized variant of the VH and VL of the antibody under i);

or B)

i) comprises a VH sequence of SEQ ID NO;

57 and a VL sequence of SEQ ID NO;

58.

ii) comprises a VH sequence of SEQ ID NO;

57 and a VL sequence of SEQ ID NO;

59.

iii) comprises a VH sequence of SEQ ID NO;

57 and a VL sequence of SEQ ID NO;

60.

iv) comprises a VH sequence of SEQ ID NO;

57 and a VL sequence of SEQ ID NO;

61.

or C)

i) comprises a VH sequence of SEQ ID NO;

15 and a VL sequence of SEQ ID NO;

16;

ii) or humanized variant of the VH and VL of the antibody under i);

or D)

i) comprises a VH sequence of SEQ ID NO;

23 and a VL sequence of SEQ ID NO;

24;

ii) or humanized variant of the VH and VL of the antibody under i);

or E)

i) comprises a VH sequence of SEQ ID NO;

31 and a VL sequence of SEQ ID NO;

32;

ii) or humanized variant of the VH and VL of the antibody under i);

or F)

i) comprises a VH sequence of SEQ ID NO;

39 and a VL sequence of SEQ ID NO;

40;

ii) or humanized variant of the VH and VL of the antibody under i);

or G)

i) comprises a VH sequence of SEQ ID NO;

47 and a VL sequence of SEQ ID NO;

48;

ii) or humanized variant of the VH and VL of the antibody under i);

or H)

i) comprises a VH sequence of SEQ ID NO;

55 and a VL sequence of SEQ ID NO;

56;

ii) or humanized variant of the VH and VL of the antibody under i).

14. An isolated antibody that binds to human PD1, wherein the antibody

i) comprises a VH sequence of SEQ ID NO:

7 and a VL sequence of SEQ ID NO;

8;

ii) or humanized variant of the VH and VL of the antibody under i);

19. The anti-PD1 antibody according to claim 14

wherein the antibody is characterized independently by one or more of the following properties:

the anti-PD-1 antibody

i) competes for binding to PD-1 with an anti-PD-1 antibody comprising the VH with the amino acid sequence of SEQ ID NO;

7 and VL with the amino acid sequence of SEQ ID NO;

8, and/or

ii) binds to a human and cynomolguoes PD-1; and

/or

iii) enhances the interferon-gamma (IFN-gamma) secretion by allogenic stimulated T cells by 85% or more at an antibody concentration of 10 μ

g/ml; and

/or

iv) enhances the tumor necrosis factor alpha (TNF alpha) secretion by allogenic stimulated T cells by 200% or more at an antibody concentration of 10 μ

g/ml.

15. An isolated antibody that binds to human PD1, wherein the antibody comprises a VH sequence of SEQ ID NO:

57 and a VL sequence of SEQ ID NO;

58.

16. An isolated antibody that binds to human PD1, wherein the antibody comprises a VH sequence of SEQ ID NO:

57 and a VL sequence of SEQ ID NO;

59.

17. An isolated antibody that binds to human PD1, wherein the antibody comprises a VH sequence of SEQ ID NO:

57 and a VL sequence of SEQ ID NO;

60.

18. An isolated antibody that binds to human PD1, wherein the antibody comprises a VH sequence of SEQ ID NO:

57 and a VL sequence of SEQ ID NO;

61.

20. An isolated antibody that binds to PD1, wherein the antibody enhances the tumor necrosis factor alpha (TNF alpha) secretion by allogenic stimulated T cells by 200% or more at an antibody concentration of 10 μ

g/ml in a Mixed lymphocyte reaction (MLR) assay.

21. An isolated antibody that binds to PD1, wherein the antibody enhances the interferon-gamma (IFN-gamma) secretion by allogenic stimulated T cells by 85% or more at an antibody concentration of 10 μ

g/ml in a Mixed lymphocyte reaction (MLR) assay.

22. An isolated antibody that binds to human PD-1, wherein the antibody:

i) competes for binding to PD-1 with an anti-PD1 antibody comprising the VH with the amino acid sequence of SEQ ID NO;

7 and VL with the amino acid sequence of SEQ ID NO;

8, and/or

ii) binds to a human and cynomolguoes PD-1; and

iii) enhances the interferon-gamma (IFN-gamma) secretion by allogenic stimulated T cells by 85% or more at an antibody concentration of 10 μ

g/ml; and

iv) enhances the tumor necrosis factor alpha (TNF alpha) secretion by allogenic stimulated T cells by 200% or more at an antibody concentration of 10 μ

g/ml.

29-32. -32. (canceled)